NDAORALCAPSULE
Approved
May 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PLACIDYL (ethchlorvynol) is an oral sedative-hypnotic capsule approved in 1961 for the short-term treatment of insomnia. The drug mechanism of action and pharmacologic class data are not currently available in clinical records. This vintage product represents a legacy hypnotic from the pre-benzodiazepine era.
LOE Approaching
Declining commercial activity with minimal team expansion expected; product is in legacy maintenance mode with 30% competitive pressure indicating significant market erosion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PLACIDYL offers minimal career acceleration; the product generates zero linked job openings and operates in a declining competitive environment. This assignment is best suited for portfolio stewardship roles focused on maximizing returns from legacy assets rather than launching or growing brands.
Brand ManagerProduct Manager
Worked on PLACIDYL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.